Triple meeting 2025 – Halda’s proximity play in prostate
Early data with the RIPTAC HLD-0915 look competitive.
Triple meeting 2025 – early efficacy signs for Quanta
The G12D-preferring QTX3034 has produced responses in endometrial and colorectal cancers.
Triple meeting 2025 – Zai discloses pivotal DLL3 plans
An upcoming second-line SCLC phase 3 will include Imdelltra as a control option.
Triple meeting 2025 – Revolution hints at post-KRAS promise
The G12C-selective elironrasib produces a 42% ORR in post-Lumakras/Krazati patients.
ESMO 2025 movers – FDA volte-face to the rescue
Redemption of sorts comes for IO Biotech, but there’s no respite for Summit.
ESMO 2025 – Sanofi takes aim at Lutathera
But Perspective sinks again.
ESMO 2025 – bemarituzumab fails to convince
Amgen and Zai Lab’s FGFR2b antibody shows no benefit at the two-year mark.
ESMO 2025 – Incyte impresses in KRAS G12D
Response rates with INCB161734 in pancreatic cancer look in line with Revolution.
ESMO 2025 – more ivonescimab shots on goal for Summit
Harmoni-6 succeeds in first-line lung cancer, but the focus is on changes to Harmoni-3.
